Aureum Diagnostics logo


Medical diagnosis is about to undergo a revolution based on the next generation of electrochemical sensors that employ electrochemical impedance spectroscopy (EIS).

Aureum Diagnostics image

Aureum Diagnostics is a spin-out company from the world-leading Innovation Centre at the University of Strathclyde. The Company will build on the work of Dr Damion Corrigan at Strathclyde University, to develop rapid, cheap, electrochemical sensors for the diagnosis of COVID and other life-threatening conditions including sepsis and heart attack.

The Aureum technology is a platform that can use many different approaches to detect a wide range of medically important molecules. For instance, the platform can be used to detect nucleic acid or detect protein targets with antibodies, receptors or aptamers. In addition to COVID tests, the company will develop tests for sepsis, a condition responsible for more deaths than lung, breast and colon cancer combined, and for Hodgkin’s disease, the commonest cancer of young adults.

ProductMedTech Growth EIS
SectorSector Medical Technology
Aim of fundingAim of funding Growth
HMRC Advanced Assurance receivedIn application
Envisaged investor exit4-5 years
Targeted returnTargeted return 7 to 15 x gross investment